NCT03586063

Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis

A Multicenter Observational Study of Diphereline 3.75 mg Treatment Effectiveness in Russian Women Suffering From Internal Genital Endometriosis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 465 (actual)
• Sponsor: Ipsen · Industry
• Sex: Female
• Age: 25 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

To describe Gonadotropin-Releasing Hormone agonists (GnRH-a) treatment effectiveness on reduction of internal genital endometriosis symptom - menorrhagia - in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3,75 mg - assessment performed six months after the last injection.

Conditions

• Internal Endometriosis

Interventions

Type	Name	Description
OTHER	Data collection	This is a non-interventional (observational) national multicentre prospective study. Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days. The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study.

Timeline

• Start date: 2011-11-03
• Primary completion: 2014-12-24
• Completion: 2014-12-24
• First posted: 2018-07-13
• Last updated: 2018-07-13

Locations

34 sites across 1 country: Russia